Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + cisatracurium
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol + cisatracurium is a combination of two separate medications used together in anesthesia protocols. Propofol is an intravenous anesthetic agent used for induction and maintenance of general anesthesia, while cisatracurium is a non-depolarizing neuromuscular blocking drug that facilitates tracheal intubation and provides skeletal muscle relaxation during surgery. When used together, propofol induces unconsciousness while cisatracurium provides muscle relaxation. These medications should not be mixed in the same syringe or administered simultaneously through the same needle.
02
Targets
GABRR (GABA-A receptor subunit rho)Muscle-type nicotinic acetylcholine receptorGABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on propofol + cisatracurium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + cisatracurium.